Trevi Therapeutics (TRVI) Competitors $9.95 +0.07 (+0.71%) Closing price 04:00 PM EasternExtended Trading$10.02 +0.07 (+0.70%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. PTGX, KYMR, MLTX, AKRO, ADMA, SRRK, MIRM, ACAD, ZLAB, and AAPGShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), MoonLake Immunotherapeutics (MLTX), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Its Competitors Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Akero Therapeutics ADMA Biologics Scholar Rock Mirum Pharmaceuticals ACADIA Pharmaceuticals Zai Lab Ascentage Pharma Group International Protagonist Therapeutics (NASDAQ:PTGX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Does the media refer more to PTGX or TRVI? In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 2 articles in the media. Protagonist Therapeutics' average media sentiment score of 1.41 beat Trevi Therapeutics' score of 0.51 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PTGX or TRVI more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Trevi Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 8.12% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics24.88% 8.12% 7.41% Trevi Therapeutics N/A -41.44%-38.21% Which has more risk and volatility, PTGX or TRVI? Protagonist Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Do analysts rate PTGX or TRVI? Protagonist Therapeutics presently has a consensus target price of $68.36, suggesting a potential upside of 6.59%. Trevi Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 118.59%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Do insiders & institutionals have more ownership in PTGX or TRVI? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, PTGX or TRVI? Protagonist Therapeutics has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$434.43M9.18$275.19M$0.7091.63Trevi TherapeuticsN/AN/A-$47.91M-$0.42-23.69 SummaryProtagonist Therapeutics beats Trevi Therapeutics on 11 of the 14 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.36B$6.16B$10.58BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-23.697.9965.0423.37Price / SalesN/A460.86612.06135.37Price / CashN/A46.3226.3031.10Price / Book7.659.9612.876.67Net Income-$47.91M-$52.42M$3.30B$276.23M7 Day Performance11.17%5.95%4.80%3.31%1 Month Performance41.94%11.59%8.11%10.76%1 Year Performance229.47%25.01%75.85%33.58% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics2.5537 of 5 stars$9.95+0.7%$21.75+118.6%+227.2%$1.20BN/A-23.6920PTGXProtagonist Therapeutics2.2518 of 5 stars$65.14-3.4%$68.36+4.9%+46.1%$4.19B$434.43M93.06120Positive NewsKYMRKymera Therapeutics1.9895 of 5 stars$58.50+4.0%$59.95+2.5%+34.5%$4.02B$47.07M-16.86170MLTXMoonLake Immunotherapeutics2.9769 of 5 stars$6.24-89.9%$57.00+813.5%-84.8%$3.98BN/A-2.242Analyst RevisionGap UpHigh Trading VolumeAKROAkero Therapeutics3.7305 of 5 stars$47.62-0.3%$81.14+70.4%+63.2%$3.82BN/A-23.8130Positive NewsAnalyst UpgradeInsider TradeADMAADMA Biologics3.7464 of 5 stars$14.70-5.8%$27.67+88.2%-27.7%$3.73B$426.45M17.09530Positive NewsSRRKScholar Rock4.414 of 5 stars$38.36-1.0%$46.40+21.0%+405.0%$3.72B$33.19M-13.18140MIRMMirum Pharmaceuticals3.5421 of 5 stars$72.85+0.1%$76.50+5.0%+85.8%$3.66B$336.89M-60.21140ACADACADIA Pharmaceuticals4.4786 of 5 stars$21.32+1.3%$29.12+36.6%+44.4%$3.55B$957.80M16.03510ZLABZai Lab3.0083 of 5 stars$32.93+4.1%$56.35+71.1%+28.0%$3.53B$398.99M-16.141,869Positive NewsAAPGAscentage Pharma Group InternationalN/A$38.55+3.3%N/AN/A$3.48B$134.35M0.00600 Related Companies and Tools Related Companies PTGX Alternatives KYMR Alternatives MLTX Alternatives AKRO Alternatives ADMA Alternatives SRRK Alternatives MIRM Alternatives ACAD Alternatives ZLAB Alternatives AAPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
